Analysts Set Expectations for AVDL Q1 Earnings

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Avadel Pharmaceuticals in a research note issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman forecasts that the company will post earnings per share of ($0.14) for the quarter. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ FY2025 earnings at $0.00 EPS, FY2027 earnings at $1.25 EPS and FY2028 earnings at $1.65 EPS.

Several other analysts also recently weighed in on AVDL. UBS Group decreased their target price on Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, January 13th. Needham & Company LLC restated a “buy” rating and issued a $19.00 price objective on shares of Avadel Pharmaceuticals in a research note on Wednesday, April 9th. HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of Avadel Pharmaceuticals in a research report on Tuesday, March 4th. Piper Sandler reduced their price target on shares of Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Avadel Pharmaceuticals in a report on Tuesday, February 11th. They set a “buy” rating and a $12.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Avadel Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $19.88.

Avadel Pharmaceuticals Price Performance

AVDL stock opened at $7.91 on Wednesday. The stock has a market capitalization of $764.34 million, a price-to-earnings ratio of -10.01 and a beta of 1.52. The company has a 50-day moving average of $8.01 and a two-hundred day moving average of $10.04. Avadel Pharmaceuticals has a 52-week low of $6.38 and a 52-week high of $19.09.

Institutional Trading of Avadel Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. FMR LLC acquired a new stake in shares of Avadel Pharmaceuticals in the 3rd quarter valued at $31,000. Hsbc Holdings PLC acquired a new position in Avadel Pharmaceuticals in the fourth quarter worth $113,000. Kazazian Asset Management LLC bought a new stake in shares of Avadel Pharmaceuticals during the fourth quarter worth $126,000. Sanctuary Advisors LLC bought a new position in shares of Avadel Pharmaceuticals in the fourth quarter valued at about $140,000. Finally, Nations Financial Group Inc. IA ADV acquired a new position in Avadel Pharmaceuticals during the 4th quarter worth about $163,000. 69.19% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Linda Palczuk bought 5,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was acquired at an average cost of $7.93 per share, with a total value of $39,650.00. Following the acquisition, the director now owns 67,900 shares in the company, valued at approximately $538,447. This represents a 7.95 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.80% of the company’s stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.